Is a major medical breakthrough on the horizon?
A new drug may prove to be a game changer in Alzheimer’s research following the results of an incredible trial.
Patients administered low-dose diranersen injections showed 54% less decline on a test of memory and thinking over nearly two years, suggesting the experimental treatment could slow the deadly disease more effectively than any therapy developed to date, per the Telegraph.
It is also the first drug to show a decline in tau, a protein that forms harmful tangles linked to brain cell death.
The diranersen injections use gene-silencing technology to confront Alzheimer’s at its source, blocking the RNA messages that signal for brain cells to produce tau.
Biogen announced the exciting results on Tuesday, Nov. 17, following the Clinical Trials on Alzheimer’s Disease 2026 conference.
“The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increasing magnitude of effect at two years,” said Priya Singhal, executive vice president and head of development at Biogen.
“These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer’s disease,” she continued.
What are scientists saying?
Professor Reisa Sperling, a co-author of the study and a professor of neurology at Harvard Medical School, who presented the brain scan findings, spoke with the Telegraph, describing the results as “thrilling.”
“These data suggest that we’re not just slowing the accumulation of tau, but we are lowering aggregated tau from baseline,” she said.
“We reversed Alzheimer pathology. We removed tau tangles. That’s a remarkable statement,” Professor Jeffrey Cummings, also a co-author of the study, told the Clinical Trials on Alzheimer’s Disease conference in Boston, according to the Telegraph.
Lawren VandeVrede, a principal investigator in the Phase 2 CELIA study at the University of California, San Francisco, called the findings “highly encouraging results, particularly given the progressive nature of Alzheimer’s disease,” per Biogen.
“The increasing separation observed between 18 months and two years is remarkable and clinically meaningful. For patients and families, slowing clinical decline means more time in early stages, preserving independence, and remaining connected to the people and experiences that matter most,” he continued.
What’s next for this treatment?
It seems that scientists will not be slowing momentum regarding this potentially life-changing new drug.
British patients are eager to join the next diranersen trial, with UK recruitment slated to begin in the spring, per the Telegraph.
Despite the overwhelming positivity, experts noted that a larger phase three trial is needed to confirm the exciting findings, though researchers said treatment in the most recent trial was well-tolerated overall.
However, some side effects did occur, including pain associated with lumbar punctures, as well as headaches and confusion, which were more prevalent at higher doses.
The new drug has the potential to make a huge impact, as over seven million Americans are living with Alzheimer’s disease, according to the Alzheimer’s Association.
This staggering number is expected to rise to almost 13 million by 2050.













